Back when AMRN had TV commercials for Vascepa they would never dare to mention any of this for fear that the FDA might not be pleased. Someday I hope that once AMRN is owned by BP they will rebrand Vascepa, perhaps in the US with a generic version, and do some skillful marketing about how any other product with EPA may be ineffective and perhaps even unsafe. Can the damage done by Judge Du and prior management be reversed in a meaningful way? Can the once great potential of Vascepa/EPA somehow be salvaged? I don't know. However, I believe the odds are far better with BP ownership. Most of us on this board understand the science...Can Alex Denner get BP to understand the science as well as most of us?
News 
Market Data 
Discover 
